A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a preliminary exploratory cohort study to evaluate safety, tolerability and
immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants Aged 18 years
and over in China
Phase:
N/A
Details
Lead Sponsor:
AIM Vaccine Co., Ltd.
Collaborators:
First Affiliated Hospital Bengbu Medical College Ningbo Rongan Biological Pharmaceutical Co. Ltd